ImmunoCellular Therapeutics Ltd (IMUC) - Financial and Strategic SWOT Analysis Review

May 2018 | 41 pages | ID: I721E37A259EN
GlobalData

Abstracts

ImmunoCellular Therapeutics Ltd (IMUC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is being developed for the treatment of glioblastoma multiforme (GBM); ICT-140, a DC vaccine designed to treat recurrent ovarian cancer; and ICT-121 for the treatment of recurrent GBM and other solid tumors. The company also develops stem cell therapies for treating cancer. As of March 2015, the development of ICT-140 has been put on hold. IMCU is headquartered in Calabasas, California, the US.

ImmunoCellular Therapeutics Ltd Key Recent Developments

May 14,2018: ImmunoCellular Therapeutics Reports First Quarter 2018 Financial Results
Apr 12,2018: ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
Mar 13,2018: ImmunoCellular Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results
Feb 13,2018: ImmunoCellular Therapeutics Announces Update on Financial Condition
Nov 21,2017: ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ImmunoCellular Therapeutics Ltd - Key Facts
ImmunoCellular Therapeutics Ltd - Key Employees
ImmunoCellular Therapeutics Ltd - Key Employee Biographies
ImmunoCellular Therapeutics Ltd - Major Products and Services
ImmunoCellular Therapeutics Ltd - History
ImmunoCellular Therapeutics Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

ImmunoCellular Therapeutics Ltd - Business Description
ImmunoCellular Therapeutics Ltd - Corporate Strategy
ImmunoCellular Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
ImmunoCellular Therapeutics Ltd - Strengths
ImmunoCellular Therapeutics Ltd - Weaknesses
ImmunoCellular Therapeutics Ltd - Opportunities
ImmunoCellular Therapeutics Ltd - Threats
ImmunoCellular Therapeutics Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
ImmunoCellular Therapeutics Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 12, 2018: ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
Feb 13, 2018: ImmunoCellular Therapeutics Announces Update on Financial Condition
Nov 21, 2017: ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results
Aug 23, 2017: ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy
Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results
May 15, 2017: ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results
Mar 09, 2017: ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

ImmunoCellular Therapeutics Ltd, Key Facts
ImmunoCellular Therapeutics Ltd, Key Employees
ImmunoCellular Therapeutics Ltd, Key Employee Biographies
ImmunoCellular Therapeutics Ltd, Major Products and Services
ImmunoCellular Therapeutics Ltd, History
ImmunoCellular Therapeutics Ltd, Subsidiaries
ImmunoCellular Therapeutics Ltd, Joint Venture
ImmunoCellular Therapeutics Ltd, Key Competitors
ImmunoCellular Therapeutics Ltd, Ratios based on current share price
ImmunoCellular Therapeutics Ltd, Annual Ratios
ImmunoCellular Therapeutics Ltd, Annual Ratios (Cont.1)
ImmunoCellular Therapeutics Ltd, Interim Ratios
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
ImmunoCellular Therapeutics Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ImmunoCellular Therapeutics Ltd, Performance Chart (2013 - 2017)
ImmunoCellular Therapeutics Ltd, Ratio Charts
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

SELLAS Life Sciences Group Inc
Cascadian Therapeutics Inc
Bavarian Nordic Washington DC Inc